QRLBIO001

Diabetic foot is one of the most significant and devastating complications of diabetes, which is characterized by ulceration of the lower limb with neuropathy and peripheral arterial disease. Diabetic foot ulcer and non-healing chronic wounds are major health problem, which occurs around 15% of the diabetes patients due to impaired wound healing and persistent inflammatory response. The condition is more frequent in older patients. It is also the major cause of diabetes associated amputation, which required prolonged hospitalization and management. Mortality following amputation is 50% and they also lose the contralateral limb within 5 years following amputation and adversely affecting the quality of life.

Early recognition and treatment of foot ulcers in diabetic patient is very critical for the successful outcome of the treatment. The conventional methods for the management of diabetic foot ulcer includes debridement of the wound, management of any infection, revascularization procedures when indicated, and off-loading of the ulcer. Other therapies such as hyperbaric oxygen therapy, advanced wound care products (skin grafts, growth factors, matrix proteins), and negative pressure wound therapy have also been used as add-on therapies. QRL Bioscience is developing a cell-based therapy-QRLBIO001 for treating Diabetic foot ulcer.